A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 720 participants.
Also called NCT03172494
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 720 participants
- Sponsor
- Registry
-
NCT03172494
-
- Other papers using this trial's data
- DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03172494. Randomized; no masking; primary purpose treatment. Start 2017-05-26 (actual); primary completion 2019-06-14 (actual). Results posted on 2020-07-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
- Acronym
- DUAL™ I China
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin degludec/liraglutide
- Intervention (Drug)
- Insulin degludec
- Intervention (Drug)
- Liraglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03172494- Content hash
5cf1f96ed011fb443eb7a13cf9b7932af8b1c7dd269269cea3b81225f27b3433